臨牀消化器内科 Vol.24 No.8(1-3)


特集名 消化管出血 -- 最近の話題
題名 総論 (3) 抗凝固薬・抗血小板薬使用者の内視鏡検査・治療
発刊年月 2009年 07月
著者 荒川 廣志 東京慈恵会医科大学内視鏡科
著者 貝瀬 満 東京慈恵会医科大学内視鏡科
著者 斉藤 彰一 東京慈恵会医科大学内視鏡科
著者 今津 博雄 東京慈恵会医科大学内視鏡科
著者 加藤 智弘 東京慈恵会医科大学内視鏡科
著者 田尻 久雄 東京慈恵会医科大学内科学講座消化器肝臓内科
【 要旨 】 日本消化器内視鏡学会の新ガイドライン「内視鏡治療時における抗血栓療法症例への対応」が平成18年に発表された.従来の指針に比して抗血栓療法の休薬による血栓塞栓症のリスクを重視し,検査前に画一的に休薬するのではなく,血栓塞栓症の再発リスクと内視鏡手技の出血リスクを評価したうえできめこまかく対応することを推奨している.当院でも新ガイドラインをもとに,外科手術の周術期管理と協同で消化器内視鏡検査時の抗血栓療法の休薬・再開指針を新たに作成し平成20年より運用を開始した.新ガイドラインの臨床的妥当性に関するエビデンスは現時点でほとんどなく,今後,多施設からのエビデンスの集積が待たれる.
Theme Topics of Gastrointestinal Hemorrhage
Title Management of Anticoagulant and Antiplatelet Agents for Endoscopic Procedures
Author Hiroshi Arakawa Department of Endoscopy, The Jikei University School of Medicine
Author Mitsuru Kaise Department of Endoscopy, The Jikei University School of Medicine
Author Shoichi Saito Department of Endoscopy, The Jikei University School of Medicine
Author Hiroo Imazu Department of Endoscopy, The Jikei University School of Medicine
Author Tomohiro Kato Department of Endoscopy, The Jikei University School of Medicine
Author Hisao Tajiri Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine
[ Summary ] In 2005, a new guideline for the managenment of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures was published by the Japan Gastroenterological Endoscopy Society (JGES). The new JGES guideline weighed the increased risk of thromboembolism caused by withdrawing anticoagulant and antiplatelet agents, and recommnded shortening cessation periods for these agents before endoscopic procedures and substituting heparin for these agents during cessation periods in cases with highly thromboembolic conditions. We established a new guideline for our university hospital in reference to the new JGES guideline in 2008. In our guideline, diagnostic endoscopy and other low risk procedures are recommended so that we may continue these agents without biopsies in cases with highly thromboembolic conditions. If there are any lesions requiring biopsy then another endoscopic examination for biopsies will be done later after stopping administration of these agents or heparin. Therapic procedures and EUS-FNA (high risk procedures) are undertaken when these agents have been stopped for seven to ten days before the procedure, the same as for perioperative management. More clinical evidence is needed to evaluate the adequacy of the new JGES guideline as well as our hospital guidelines.
戻る